Jiafeng Gao

Jiafeng Gao

Auto-generated profile, based on publicly available information

Jiafeng Gao

The Clinical Department, College of Veterinary Medicine, China Agricultural University, Beijing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2019 in Cell Proliferation
Verified
Journal Article
Open access
PDF file
HDHaodi Dong
Haodi Dong
HDHongxiu Diao
Hongxiu Diao
YZYing Zhao
Ying Zhao
HXHuihao Xu
Huihao Xu
SPShimin Pei
Shimin Pei
DLDegui Lin
Degui Lin
Objectives: Matrix metalloproteinase 9 (MMP‐9) has been frequently noticed in the breast cancers. In this study, we aim to investigate the associations of MMP‐9 with the activation of transforming growth factor beta (TGF‐β)/SMAD signalling and the malignancy of breast malignant tumour cells.Materials and methods: The distributions of MMP‐9 and TGF‐β in the tissues of canine breast cancers were screened by immunohistochemical assays. A recombinant plasmid expressing mouse MMP‐9 was generated and transiently transfected into three different breast cancer cell lines. Cell Counting Kit‐8 and colony formation assay were used to study cell viability. Migration and invasion ability were analysed by wound assay and transwell filters. Western blot and quantitative real‐time PCR were used to determine the protein and mRNA expression.Result: Remarkable strong MMP‐9 and TGF‐β signals were observed in the malignant tissues of canine breast cancers. In the cultured three cell lines receiving recombinant plasmid expressing mouse MMP‐9, the cell malignancy was markedly increased, including the cell colony formation, migration and epithelial‐mesenchymal transition. The levels of activated TGF‐β, as well as SMAD4, SMAD2/3 and phosphorylation of SMAD2, were increased, reflecting an activation of TGF‐β/SMAD signalling. We also demonstrated that the inhibitors specific for MMP‐9 and TGF‐β sufficiently blocked the overexpressing MMP‐9 induced the activation of SMAD signalling and enhancement on invasion in the tested breast cancer cell lines.Conclusion: Overexpression of MMP‐9 increases the malignancy of breast cancer cell lines, largely via activation of the TGF‐β/SMAD signalling.

1 December 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
JGJiafeng Gao
Jiafeng Gao
KFKai Fan
Kai Fan
YJYipeng Jin
Yipeng Jin
LZLinna Zhao
Linna Zhao
QWQian Wang
Qian Wang
DLDegui Lin
Degui Lin

14 March 2019 in Cell Proliferation
Verified
Journal Article
Open access
PDF file
JLJiahao Lin
Jiahao Lin
LMLie Ma
Lie Ma
DZDi Zhang
Di Zhang
LJLin Jiahao
Lin Jiahao
YJYipeng Jin
Yipeng Jin
DLDegui Lin
Degui Lin
In recent years, with the increase in cancer mortality caused by metastasis, and with the development of individualized and precise medical treatment, early diagnosis with precision becomes the key to decrease the death rate. Since detecting tumour biomarkers in body fluids is the most non‐invasive way to identify the status of tumour development, it has been widely investigated for the usage in clinic. These biomarkers include different expression or mutation in microRNAs (miRNAs), circulating tumour DNAs (ctDNAs), proteins, exosomes and circulating tumour cells (CTCs). In the present article, we summarized and discussed some updated research on these biomarkers. We overviewed their biological functions and evaluated their multiple roles in human and small animal clinical treatment, including diagnosis of cancers, classification of cancers, prognostic and predictive values for therapy response, monitors for therapy efficacy, and anti‐cancer therapeutics. Biomarkers including different expression or mutation in miRNAs, ctDNAs, proteins, exosomes and CTCs provide more choice for early diagnosis of tumour detection at early stage before metastasis. Combination detection of these tumour biomarkers may provide higher accuracy at the lowest molecule combination number for tumour early detection. Moreover, tumour biomarkers can provide valuable suggestions for clinical anti‐cancer treatment and execute monitoring of treatment efficiency.

18 December 2023 in Oncology Letters
Verified
Journal Article
Open access
PDF file
LJLin Jiahao
Lin Jiahao
ZHZhen Huo
Zhen Huo
XSXueyi Song
Xueyi Song
QSQianqian Shao
Qianqian Shao
WRWeiwei Ren
Weiwei Ren
XTXiaolong Tang
Xiaolong Tang
Epidermal growth factor receptor (EGFR) is expressed in various types of cancer and is associated with the malignant biological behavior of cancer cells. In the present study, the expression of EGFR in hepatocellular carcinoma (HCC) tissues and liver cancer cells was detected by immunohistochemical staining, western blotting and immunofluorescence. Furthermore, a lentivirus was transduced into HepG2 liver cancer cells to knock down EGFR expression. Cell proliferation and migration, and the expression levels of epithelial‑mesenchymal transition (EMT) markers were assessed by EdU staining, Cell Counting Kit‑8, colony formation, wound healing and Transwell assays, and western blotting. The results revealed that EGF/EGFR can mediate EMT through the Akt/glycogen synthase kinase‑3β (GSK-3β)/Snail signaling pathway to promote HepG2 cell proliferation and migration. Inhibition of the activation of the EGFR signaling pathway can help to partially reverse the EMT phenotype, and inhibit the proliferation and migration of HepG2 cells. In conclusion, the EGFR/Akt/GSK-3β/Snail signaling pathway serves an important role in HCC progression, and inhibition of the activation of the EGFR signaling pathway may be a valuable strategy in liver cancer treatment.